Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial Prof Ignace Vergote, MD PhDa,* Send email to ignace.vergote@kuleuven.be ∙ Prof David Cibula, MD PhDb ∙ Prof Matthew Powell, MDc ∙ Annouschka Laenen, PhDa ∙ Prof Els Van Nieuwenhuysen, MD PhDa ∙ Prof Samet Topuz, MDd ∙ et al.

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial Prof Ignace Vergote, MD PhDa,* Send email to ignace.vergote@kuleuven.be ∙ Prof David Cibula, MD PhDb ∙ Prof Matthew Powell, MDc ∙ Annouschka Laenen, PhDa ∙ Prof Els Van Nieuwenhuysen, MD PhDa ∙ Prof Samet Topuz, MDd ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00223-8/abstract?dgcid=raven_jbs_etoc_feature_lanonc